How Labcorp Became More Than a Partner to Deliver a New Oncology Molecule

A leading pharmaceutical company was developing several molecules for the treatment of a hematologic malignancy. With the goal of supporting two lead compounds in Phase I first-in-human trials, with no disruption or lost time, the client selected Labcorp as their partner. This case study shares how Labcorp delivered scientific expertise and flexibly responded to challenges, managing two parallel trials that quickly grew into a suite of studies spanning early clinical development to late-stage development.

Filed In

Phase I & FIH
Phase IIa